Several independent clinical studies measuring circulating levels of FABP4, have demonstrated that an elevation in circulating FABP4 and an increase in serum lipids, inflammatory markers MCP-1 and hsCRP are strongly associated in patients with metabolic dysregulations such as atherosclerosis, type 2 diabetes and dyslipidemias. This evidence concerns the gene FABP4 and metabolic syndrome.